FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia
Top Cited Papers
Open Access
- 15 August 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 110 (4), 1262-1270
- https://doi.org/10.1182/blood-2006-04-015826
Abstract
The prognostic impact of tyrosine kinase domain (TKD) mutations of the fms-like tyrosine kinase-3 (FLT3) gene in acute myeloid leukemia (AML) is currently uncertain. To resolve this issue we screened 1107 young adult nonacute promyelocytic leukemia AML patients with known FLT3 internal tandem duplication (ITD) status for FLT3/TKDs; they were detected in 127 (11%) cases. Mutations were associated with a high white cell count (P =.006) and patients with inv(16) (P = .005) but were infrequent in patients with adverse cytogenetics and secondary AML. Overall survival (OS) at 5 years was 53% and 37% for FLT3/TKD mutant and wild-type patients respectively (odds ratio, 0.72; 95% confidence interval, 0.58 to 0.89; P = .002). For both the cumulative incidence of relapse and OS the difference in outcome between FLT3/ITDs and FLT3/TKDs was highly significant (P < .001). In multivariate analysis, impact of FLT3/TKDs on OS when including all mutant-positive patients was not significant, but patients with high-level mutations (more than 25% mutant) had a significantly improved outcome (P = .004). The novel finding that biologically distinct activating mutations of the same gene can be associated with markedly different clinical outcomes has implications for risk stratification and therapy and is significant to the understanding of chemoresistance in AML.Keywords
This publication has 34 references indexed in Scilit:
- Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemiaBlood, 2005
- More flitting about FLT3Blood, 2005
- Rapid and sensitive detection of internal tandem duplication and activating loop mutations of FLT3British Journal of Haematology, 2005
- Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotypeOncogene, 2005
- The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane DomainMolecular Cell, 2004
- FLT3: ITDoes matter in leukemiaLeukemia, 2003
- The role of FLT3 in haematopoietic malignanciesNature Reviews Cancer, 2003
- Prognostic significance of FLT3 ITD and D835 mutations in AML patientsThe Hematology Journal, 2003
- A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemiaBlood, 2002
- Catalytic specificity of protein-tyrosine kinases is critical for selective signallingNature, 1995